MIRA maintains an asset-light structure with no significant debt, yet its financial flexibility is severely constrained by an accumulated deficit that reached $40.7 million as of 2026Q1.
| Total Current Assets | 9.43M | 11.06M | 2.89M | 4.86M | 494.4K | 2.91M | 3.49K |
| Cash & Short-Term Investments | 9.41M | 6.35M | 2.83M | 4.6M | 350.98K | 2.81M | 3.49K |
| Cash Only | 4.82M | 6.35M | 2.83M | 4.6M | 350.98K | 2.81M | 3.49K |
| Short-Term Investments | 4.59M | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Sales Outstanding | - | - | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - |
| Other Current Assets | 21.75K | 4.71M | 0 | 11.86K | 143.43K | 100K | 0 |
| Total Non-Current Assets | 35.44K | 35.44K | 35.44K | 74.21K | 363.67K | 445.61K | 18.88K |
| Property, Plant & Equipment | 0 | 0 | 0 | 5.06K | 363.67K | 0 | 0 |
| Fixed Asset Turnover | - | - | - | - | - | - | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 35.44K | 0 | 35.44K | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 35.44K | 35.44K | 0 | 69.15K | 0 | 445.61K | 18.88K |
| Total Assets | 9.46M | 11.09M | 2.92M | 4.93M | 858.07K | 3.36M | 22.37K |
| Asset Turnover | 0.00x | - | - | - | - | - | - |
| Asset Growth % | 863.04% | 279.52% | -40.74% | 474.83% | -74.43% | 14897.83% | - |
| Total Current Liabilities | 114.76K | 702.07K | 723.35K | 558.1K | 1.37M | 1.09M | 90.36K |
| Accounts Payable | 0 | 0 | 723.35K | 538.56K | 905.55K | 228.41K | 0 |
| Days Payables Outstanding | - | - | - | - | - | - | - |
| Short-Term Debt | 0 | 0 | 0 | 0 | 133.06K | 293.06K | 90K |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 114.76K | 702.07K | 0 | 0 | 0 | 0 | 0 |
| Current Ratio | 82.16x | 15.75x | 3.99x | 8.70x | 0.36x | 2.66x | 0.04x |
| Quick Ratio | 82.16x | 15.75x | 3.99x | 8.70x | 0.36x | 2.66x | 0.04x |
| Cash Conversion Cycle | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 0 | 0 | 0 | 0 | 84.27K | 0 | 0 |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 84.27K | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 114.76K | 702.07K | 723.35K | 558.1K | 1.45M | 1.09M | 90.36K |
| Total Debt | 0 | 0 | 0 | 5.06K | 491.23K | 293.06K | 90K |
| Net Debt | -4.82M | -6.35M | -2.83M | -4.6M | 140.25K | -2.52M | 86.51K |
| Debt / Equity | 0.00x | - | - | 0.00x | - | 0.13x | - |
| Debt / EBITDA | -0.00x | - | - | - | - | - | - |
| Net Debt / EBITDA | 0.49x | - | - | - | - | - | - |
| Interest Coverage | - | - | -48.40x | -2.47x | -687.60x | -88.30x | -185.79x |
| Total Equity | 9.35M | 10.39M | 2.2M | 4.37M | -596.23K | 2.26M | -67.99K |
| Equity Growth % | 1031.72% | 372.4% | -49.71% | 833.67% | -126.37% | 3425.87% | - |
| Book Value per Share | 0.22 | 0.44 | 0.14 | 0.24 | -0.04 | 0.15 | -0.00 |
| Total Shareholders' Equity | 9.35M | 10.39M | 2.2M | 4.37M | -596.23K | 2.26M | -67.99K |
| Common Stock | 4.2K | 4.19K | 1.66K | 1.48K | 6.66K | 6.34K | 5.89K |
| Retained Earnings | -40.73M | -39.58M | -29.14M | -21.29M | -9.3M | -2.24M | -67.99K |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 | 0 | -5.89K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Binary clinical trial failure
As reported in recent financial filings, MIRA's total assets have fluctuated from $11.1 million in 2025Q4 to $9.5 million in 2026Q1, reflecting a rapid depletion of resources that signals a weakening balance sheet trajectory as the company continues to fund its pre-revenue clinical development activities.
The contraction in total assets over the most recent quarter suggests that the company is consuming its capital base at a rate that outpaces its ability to replenish it through non-dilutive means. This downward trend in asset value warrants close monitoring, as it directly correlates with the firm's limited runway to achieve meaningful clinical milestones.
Based on the company's reported figures, cash reserves have declined from $6.3 million in 2025Q4 to $4.8 million in 2026Q1, indicating that the firm's liquidity buffer is shrinking rapidly and may necessitate an imminent capital raise to sustain ongoing research and development operations.
While the current ratio remains high due to minimal liabilities, this metric is deceptive for a pre-revenue entity where cash is the only meaningful liquid asset. The rapid decline in cash suggests that the company's operational burn is accelerating, leaving little room for error in clinical trial execution or unexpected regulatory delays.
According to the balance sheet data, MIRA's retained earnings have reached a deficit of $40.7 million as of 2026Q1, which highlights the significant capital destruction inherent in the company's current business model and underscores the reliance on external equity financing to maintain a positive book value.
The persistent growth of the accumulated deficit reflects the high cost of clinical-stage drug development without any offsetting revenue streams. Investors should interpret this as a signal that the equity base is essentially a vehicle for funding future binary outcomes, with little intrinsic value currently supported by operational performance.
As indicated by the absence of significant PPE or goodwill on the balance sheet, MIRA operates an asset-light model that, while avoiding capital-intensive maintenance, leaves the company entirely exposed to the binary risk of clinical trial failure without any tangible assets to provide a valuation floor.
The lack of physical assets suggests that the company's value is tied exclusively to its intellectual property and the potential of MIRA1a. This structure makes the balance sheet highly sensitive to regulatory setbacks, as there are no secondary revenue-generating assets to mitigate the impact of a failed clinical program.
Quick answers to the most common questions about buying MIRA stock.
As of 2025, MIRA Pharmaceuticals, Inc. (MIRA) had total assets of $11.1M including $11.1M in current assets.
MIRA Pharmaceuticals, Inc. (MIRA) carries total debt of $0.0M, offset by $6.3M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
MIRA Pharmaceuticals, Inc. (MIRA) has total shareholders' equity (book value) of $10.4M ($0.44 book value per share). Book value represents the net worth of the company belonging to common stock holders.
MIRA Pharmaceuticals, Inc. (MIRA) reported a current ratio of 15.75x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.